Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluating the Impact of JJVC Senofilcon A - Based Contact Lens With New UV-blocker on Day and Night Driving Performance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03330275
Recruitment Status : Completed
First Posted : November 6, 2017
Results First Posted : August 7, 2018
Last Update Posted : August 7, 2018
Sponsor:
Information provided by (Responsible Party):
Johnson & Johnson Vision Care, Inc.

Brief Summary:
This is a bilateral, non-dispensing, randomized, subject masked, four visits, 3-period by 3- treatment crossover study. The objective of this study is to evaluate the effect of JJVC senofilcon A - based contact lens with new UV-blocker on vision and driving performance in both daytime and nighttime lighting under real world driving conditions. This will be achieved through field-based driving studies on a closed-road driving circuit at night and during the day. Quantitative methods will be used to assess vision and driving performance under a range of challenging conditions and appropriate masking, order of testing, randomization and control conditions will be used.

Condition or disease Intervention/treatment Phase
Visual Performance Device: Investigational Contact Lens Device: Commercial ACUVUE OASYS Device: Commercial ACUVUE OASYS and Spectacles Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Evaluating the Impact of JJVC Senofilcon A - Based Contact Lens With New UV-blocker on Day and Night Driving Performance
Actual Study Start Date : September 27, 2017
Actual Primary Completion Date : December 11, 2017
Actual Study Completion Date : December 11, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eye Wear

Arm Intervention/treatment
Experimental: Test/Control 1/Control 2
Subjects will be randomized to 1 of 3 lenses (Test/Control 1/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
Device: Investigational Contact Lens
JJVC senofilcon A-based contact lens with new UV-blocker
Other Name: Test

Device: Commercial ACUVUE OASYS
senofilcon A
Other Name: Control 1

Device: Commercial ACUVUE OASYS and Spectacles
Senofilcon A and Spectacles
Other Name: Control 2

Experimental: Test/Control 2/Control 1
Subjects will be randomized to 1 of 3 lenses (Test/Control 2/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
Device: Investigational Contact Lens
JJVC senofilcon A-based contact lens with new UV-blocker
Other Name: Test

Device: Commercial ACUVUE OASYS
senofilcon A
Other Name: Control 1

Device: Commercial ACUVUE OASYS and Spectacles
Senofilcon A and Spectacles
Other Name: Control 2

Experimental: Control 1/Test/Control 2
Subjects will be randomized to 1 of 3 lenses (Control 1/Test/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
Device: Investigational Contact Lens
JJVC senofilcon A-based contact lens with new UV-blocker
Other Name: Test

Device: Commercial ACUVUE OASYS
senofilcon A
Other Name: Control 1

Device: Commercial ACUVUE OASYS and Spectacles
Senofilcon A and Spectacles
Other Name: Control 2

Experimental: Control 1/Control 2/Test
Subjects will be randomized to 1 of 3 lenses (Control 1/Control 2/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
Device: Investigational Contact Lens
JJVC senofilcon A-based contact lens with new UV-blocker
Other Name: Test

Device: Commercial ACUVUE OASYS
senofilcon A
Other Name: Control 1

Device: Commercial ACUVUE OASYS and Spectacles
Senofilcon A and Spectacles
Other Name: Control 2

Experimental: Control 2/Test/Control 1
Subjects will be randomized to 1 of 3 lenses (Control 2/Test/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
Device: Investigational Contact Lens
JJVC senofilcon A-based contact lens with new UV-blocker
Other Name: Test

Device: Commercial ACUVUE OASYS
senofilcon A
Other Name: Control 1

Device: Commercial ACUVUE OASYS and Spectacles
Senofilcon A and Spectacles
Other Name: Control 2

Experimental: Control 2/Control 1/Test
Subjects will be randomized to 1 of 3 lenses (Control 2/Control 1/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
Device: Investigational Contact Lens
JJVC senofilcon A-based contact lens with new UV-blocker
Other Name: Test

Device: Commercial ACUVUE OASYS
senofilcon A
Other Name: Control 1

Device: Commercial ACUVUE OASYS and Spectacles
Senofilcon A and Spectacles
Other Name: Control 2




Primary Outcome Measures :
  1. Overall Nighttime Driving Score [ Time Frame: 15 Minutes Post Lens Fitting ]
    Overall driving performance score is a composite score calculated as the mean of the Z-scores of the following six driving measures: average sign recognition distance (in meters), percentage of correctly identified sign (~42 signs), percentage of hazard avoidance/detection (9 hazards), average pedestrian recognition distance (in meters), lane keeping (percentage of time inside the lane) and the inverse of driving lap time (in seconds).). Equal weighting was assigned to each measure. The individual Z scores were transformed (inverted) such that positive Z scores relate to better performance than the mean. Z scores follow a standard normal distribution (ranging from minus infinity to positive infinity). Overall Z score for night time driving was reported for each study lens.


Secondary Outcome Measures :
  1. Binocular Visual Acuity [ Time Frame: 15 Minutes Post Lens Fitting ]
    Binocular visual acuity was assessed under Low luminance (~1 lux) high contrast (90%) conditions at a distance of 4 meters. The ETDRS logMAR chart were used, which is scored on a letter by letter basis (-0.02 log units per letter correctly identified). A number of different EDTRS charts was used to reduce potential learning effects. The average LogMAR acuity for each lens was reported.

  2. Binocular Contrast Threshold Without Glare [ Time Frame: 15 Minutes Post Lens Fitting ]
    Binocular contrast sensitivity was assessed under low luminance conditions. Five Landolt C targets in random orientation were presented for each of the four contrast levels 95%, 80%, 63% and 50%. Participants were asked to correctly identify the orientation of the Landolt C. The percentage of subjects that were able to correct identify the orientation of all 5 Landolt's C was reported for each lens type.

  3. Percentage of Road Signs Correctly Identified During Night Driving [ Time Frame: 15 Minutes Post Lens Fitting ]
    Participants were instructed to report the identity of a percentage of the standard road signs (typically about 42 signs dependent on the route travelled) containing about 65 items of information as they drove around the circuit. The percentage of correctly identified signs was reported for each study lens.

  4. Average Distance to Correctly Identify Road Signs During Night Driving [ Time Frame: 15 Minutes Post Lens Fitting ]
    Measure Description The distance (measured in meters) to recognize a pre-determined road sign was recorded for each subject and lens type at either visit 3 or visit 4, using the in-vehicle measurement system while the participant was driving. The in-vehicle measurement system consisted of a subject pressing a button once the subject was able to recognize the road sign. The average distance in meters was reported for each lens type. Larger distance indicate that a subject was able to identify the pre-determined road sign sooner.

  5. Percentage of Hazards Avoided During Night Driving [ Time Frame: 15 Minutes Post Lens Fitting ]
    Participants were required to report and avoid hitting any of nine large, low contrast grey foam "hazards" (220 cm x 80 cm x 15 cm) positioned orthogonally in the driving lane along the roadway, the locations of which will be randomized between study lenses. The percentage of Hazards avoided for each study lens was reported.

  6. Average Pedestrian Recognition Distance [ Time Frame: 15 Minutes Post Lens Fitting ]
    The in-vehicle measurement system was utilized to determine the distance at which the participant (as a driver) first recognizes the presence of two pedestrians positioned at the side of the road. An experimenter acted as the pedestrian and "walked in-place" at the end of a 400 m straight section of roadway which starts and finishes at approximately the same elevation, but features a dip halfway along its length. The pedestrian was not surrounded by any visual clutter or lighting. To reduce expectancy effects, a series of four flashing LEDs and four retro-reflective bollards was positioned around the circuit to increase the instances of flashing lights and retro-reflective material being presented to the driver. The average distance to recognize a pedestrian for each lens type was reported.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Potential subjects must satisfy all of the following criteria to be enrolled in the study:

    1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
    2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
    3. Between 20 and 49 (inclusive) years of age at the time of screening.
    4. Presbyopic subjects must be habitual wearers of distance vision correction in both eyes.
    5. The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 through -6.00 D (inclusive) in each eye.
    6. The subject's refractive cylinder must be ≤ 1.00 D in each eye.
    7. Have spherocylindrical best corrected visual acuity of 20/20 or better in each eye.
    8. Be a current soft contact lens wearer in both eyes, defined as at least 5 days per week and 6 hours per day averaged over the past 30 days.
    9. Hold a current Open driver's license
    10. Be a regular driver (at least once per week)
    11. Have at least one year of driving experience

      Exclusion Criteria:

  • Potential subjects who meet any of the following criteria will be excluded from participating in the study:

    1. Currently pregnant or lactating
    2. Any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study.
    3. Use of systemic medications (e.g., chronic steroid use) that are known to interfere with contact lens wear, pupil size or accommodation.
    4. Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion.
    5. History of binocular vision abnormality or strabismus
    6. Any current use of ocular medication
    7. Any previous, or planned (during the course of the study) ocular surgery (e.g., radial keratotomy, PRK, LASIK, etc.)
    8. Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA slit lamp biomicroscopy scale
    9. Any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that would contraindicate contact lens wear
    10. Employee of clinical site (e.g., Investigator, Coordinator, Technician)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03330275


Locations
Layout table for location information
Australia, Queensland
Queensland University of Technology, School of Optometry and Vision Science
Brisbane, Queensland, Australia
Sponsors and Collaborators
Johnson & Johnson Vision Care, Inc.
  Study Documents (Full-Text)

Documents provided by Johnson & Johnson Vision Care, Inc.:
Study Protocol  [PDF] September 14, 2017
Statistical Analysis Plan  [PDF] December 26, 2017


Layout table for additonal information
Responsible Party: Johnson & Johnson Vision Care, Inc.
ClinicalTrials.gov Identifier: NCT03330275     History of Changes
Other Study ID Numbers: CR-5830
First Posted: November 6, 2017    Key Record Dates
Results First Posted: August 7, 2018
Last Update Posted: August 7, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: Yes